European Journal of Biomedical and Pharmaceutical Sciences

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): A COMPREHENSIVE REVIEW

Devdat, Oluwamayowa Bababunmi, Ransirini Tharaka Wijeratne, Madinah Suleiman Usman, Huda Ijaz*, Chidinma Vivian Ikekpeazu, Vivian Samuel Hana Abdelmalak, Mohammed Numaan Ahmed, Taiwo Ogundipe, Nosike C. Obionwu, Abeeb Babatunde Oyedele, Edmund Umebani, Aqsa Latif, Adewale Mark Adedoyin9 and Hammad Zafar

ABSTRACT

In Western countries, the commonest cause of chronic liver disease (CLD) is non-alcoholic fatty liver disease (NAFLD). Ongoing research related to it has enhanced our understanding of the disease progression as well as the effect of this entity on overall morbidity and mortality. NAFLD in its active form is known as nonalcoholic steatohepatitis (NASH), for which, according to the European Medicine Agency, there is no recommended treatment currently. Developing new treatments is challenging as the condition progresses slowly. New data must be used to improve our understanding of the elements that influence the development of NAFLD. This may allow for a more accurate and non-invasive assessment of prognosis. For targeted individual treatment, assessments focussing particularly on populations that are at risk of developing NAFLD are available. The goal of this review paper is to highlight recent discoveries in the field of NAFLD, including pathogenesis, epidemiology, and treatment options. The diagnosis, clinical characteristics, and existing treatment options, including novel targets and medicines, are all discussed.

Keywords: Hepatology, Nonalcoholic fatty liver disease, Review.